TELORYX
Contact us
Protocols Single peptides Blends Stacks Encyclopedia Calculator Guides Master chart
CategoriesMetabolic & Weight LossExperimental ResearchHealing & RecoveryBioregulatorsBrain Health & NootropicsGrowth Hormone & PerformanceSkin & CosmeticHormonal & Sexual HealthImmune & InflammationLongevity & Mitochondrial Health
Contact us

Encyclopedia · Experimental Research

IGF-1 DES

IGF-1 DES, known in the literature as des(1–3)IGF-I or IGF-1(4–70), is a truncated variant of insulin-like growth factor 1 missing the first three amino acids of the native, full-length hormone. [1] Native IGF-1 is a 70-amino-acid protein; IGF-1 DES is a shortened 67-amino-acid version missing a small tripeptide from one end. That small structural change matters biologically because it alters how the molecule interacts with IGF-binding proteins — the carrier proteins that normally regulate how much IGF-1 is available to act on tissue. IGF-1 DES should not be confused with mecasermin, the only FDA-approved recombinant IGF-1 drug, or with IGF-1 LR3, a different engineered IGF-1 analog.

What It Is

IGF-1 DES, known in the literature as des(1–3)IGF-I or IGF-1(4–70), is a truncated variant of insulin-like growth factor 1 missing the first three amino acids of the native, full-length hormone.[1] Native IGF-1 is a 70-amino-acid protein; IGF-1 DES is a shortened 67-amino-acid version missing a small tripeptide from one end.

That small structural change matters biologically because it alters how the molecule interacts with IGF-binding proteins — the carrier proteins that normally regulate how much IGF-1 is available to act on tissue. IGF-1 DES should not be confused with mecasermin, the only FDA-approved recombinant IGF-1 drug, or with IGF-1 LR3, a different engineered IGF-1 analog.

How It Works

Like native IGF-1, IGF-1 DES is believed to act through the IGF-1 receptor, a receptor tyrosine kinase that triggers intracellular signaling involved in cell growth, protein synthesis, and glucose uptake. Its distinguishing feature is reduced binding to IGF-binding proteins: in a classic biochemical study, these binding proteins blocked the activity of native IGF-1 and IGF-2 but did not inhibit des(1-3)IGF-1 the same way.[3] That reduced interaction is thought to leave more of the molecule freely available to act on receptors, which is why some laboratory studies found it roughly ten-fold more potent than native IGF-1 at stimulating cell growth.

Because IGF-1 signaling overlaps with skeletal muscle protein synthesis and satellite-cell pathways, IGF-1 DES is frequently discussed in the context of muscle hypertrophy. That mechanistic overlap is real, but it describes a laboratory pathway, not a demonstrated human outcome.

What the Research Shows

Human clinical research specific to IGF-1 DES is essentially absent. The available literature is dominated by biochemical, cell-culture, and animal-model studies: rodent research has examined IGF-1 DES for enhancing growth after small-bowel resection and in models of renal insufficiency.[7]

None of this constitutes evidence for muscle growth, fat loss, recovery, or anti-aging benefits in people — claims commonly made in bodybuilding and peptide-marketing content. Separately, animal research found that IGF-1 variants with reduced binding-protein interaction produced stronger and more prolonged blood-sugar-lowering effects than native IGF-1, a safety signal rather than a benefit finding. Approved human IGF-1 evidence exists only for mecasermin, a different, full-length molecule with its own narrow pediatric indication, and that evidence does not transfer to IGF-1 DES.

Safety & Side Effects

No well-defined human safety profile exists for IGF-1 DES. Risk assessment must be extrapolated from IGF-1 biology, mecasermin's prescribing label, and animal data, which point to several plausible concerns:

  • Hypoglycemia, since IGF-1 has insulin-like, blood-sugar-lowering effects; mecasermin's label warns of severe hypoglycemia and hypoglycemic seizures
  • Tissue overgrowth, including lymphoid tissue hypertrophy noted with mecasermin
  • Abnormal cell proliferation, given the IGF-1 receptor's established role in cancer biology
  • Injection-site reactions and local tissue changes
  • Unknown product quality, since IGF-1 DES sold outside regulated channels is not manufactured or tested to pharmaceutical standards

People with diabetes, cancer history, or those on glucose-lowering medications face particular theoretical risk, and no monitoring protocol for IGF-1 DES exists in humans.

Regulatory Status

IGF-1 DES is not an FDA-approved drug and has no labeled indication for muscle growth, recovery, bodybuilding, or any other use. The only FDA-approved IGF-1 medicine is mecasermin (Increlex), and its approval is narrow: pediatric patients two years and older with severe primary IGF-1 deficiency, or growth hormone gene deletion with neutralizing antibodies to growth hormone.[13] That approval belongs to a structurally different molecule and does not extend to IGF-1 DES.

IGF-1 and its analogues, including des(1-3)IGF-1, also appear on the World Anti-Doping Agency's Prohibited List, reflecting anti-doping policy distinct from medical safety review.[18] Products marketed online as research-grade IGF-1 DES fall outside FDA oversight for identity, purity, and manufacturing quality.